rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Biogen Inc.

BIIB · Nasdaq

Health CareBiotechnologyLeading

BIIB stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 19.7% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
52 in a row
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$1,170
Insider sales, 12 months
$1.8M
Officials’ trades on record
157

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

157 disclosed lines: House 127, Senate 24, executive 6; 34 people.

WhoDidAmountTraded
Maria Elvira Salazar House: U.S. House ClerkFL27sold$1k–$15k24 Sep 2026filed 7 Oct 2026
Kevin Hern House: U.S. House ClerkOK01sold$1k–$15k18 Aug 2026filed 1 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k12 Jun 2026filed 22 Aug 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k5 Jun 2026filed 2 Jul 2026
Maria Elvira Salazar House: U.S. House ClerkFL27sold$15k–$50k2 Jun 2026filed 7 Jul 2026
Maria Elvira Salazar House: U.S. House ClerkFL27bought$1k–$15k12 May 2026filed 8 Jun 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k11 May 2026filed 1 Jul 2026
Maria Elvira Salazar House: U.S. House ClerkFL27bought$1k–$15k11 May 2026filed 8 Jun 2026
Maria Elvira Salazar House: U.S. House ClerkFL27bought$50k–$100k11 May 2026filed 8 Jun 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k15 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k10 Apr 2026filed 1 Jul 2026
Alan Armstrong Senate: U.S. Senate eFDSenatorbought$1k–$15k27 Mar 2026filed 21 Jul 2026

Insiders

Buy orders, 12 months1
Sale orders, 12 months4
Buyers · sellers1 · 2
WhoDidSharesTraded
Lloyd MinorDirectorsold593at $200.964 Aug 2026filed 5 Aug 2026
Lloyd MinorDirectorsold593at $203.343 Aug 2026filed 5 Aug 2026
Nicole MurphyHead of Pharm Ops and Techbought3at $195.0412 Feb 2026filed 17 Feb 2026
Priya SinghalHead of Developmentsold2,660at $199.839 Feb 2026filed 10 Feb 2026
Priya SinghalHead of Developmentsold748at $179.302 Feb 2026filed 3 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

News

Everyone who traded it

Sean Godbout Company insiderChief Accounting Officer · last 2 Oct 20260 · 0
Maria Elvira Salazar HouseFL27 · last 24 Sep 20263 · 2
Michael Parini Company insiderChief Legal Officer · last 1 Sep 20260 · 0
Kevin Hern HouseOK01 · last 18 Aug 20260 · 1
Lloyd Minor Company insiderDirector · last 4 Aug 20260 · 2
Donald J. Trump Executive branchWhite House Office · last 12 Jun 20262 · 2
Eric K. Rowinsky Company insiderDirector · last 9 Jun 20261 · 6
Jesus B. Mantas Company insiderDirector · last 9 Jun 20261 · 0
Maria C. Freire Company insiderDirector · last 9 Jun 20260 · 0
Menelas N. Pangalos Company insiderDirector · last 9 Jun 20260 · 0
Monish D. Patolawala Company insiderDirector · last 9 Jun 20260 · 0
Stephen A. Sherwin Company insiderDirector · last 9 Jun 20260 · 9

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202575.7%
Free cash flow marginFY 2025 · to 31 Dec 202520.7%
Cash conversionFY 2025 · to 31 Dec 2025171%
Debt to equityFY 2025 · to 31 Dec 20250.34×
Share count trendFY 2025 · to 4 Feb 2026-0.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$3.0B
Free cash flowFY 2025 · to 31 Dec 2025$2.1B

Analyst forecasts

No analyst forecasts yet.